NO20041941L - Doseringsform, utstyr og fremgangsmater for behandling - Google Patents

Doseringsform, utstyr og fremgangsmater for behandling

Info

Publication number
NO20041941L
NO20041941L NO20041941A NO20041941A NO20041941L NO 20041941 L NO20041941 L NO 20041941L NO 20041941 A NO20041941 A NO 20041941A NO 20041941 A NO20041941 A NO 20041941A NO 20041941 L NO20041941 L NO 20041941L
Authority
NO
Norway
Prior art keywords
formulation
active agent
rumen
amounts
predetermined
Prior art date
Application number
NO20041941A
Other languages
English (en)
Inventor
Lionel Barry Lowe
Joseph Raymond Winkle
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3832213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20041941(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20041941L publication Critical patent/NO20041941L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0068—Rumen, e.g. rumen bolus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse angår et kontrollert doseringsfrigivelseselement tilpasset å bli innsatt i og holdes i vommen til en drøvtygger. Elementet innbefatter: a) en eller flere adskilte og forhåndsbestemte mengder av minst en første formulering som innbefatter minst et første aktivt middel, formuleringen er tilpasset til å bli løst opp i vomfluider i en hastighet slik at oppløsningen av hver av den ene eller flere mengder av den første formuleringen gir en kort eller pulset frigivningsepisode av det første aktive middel inn i vommen; og b) en eller flere forhåndsbestemte mengder av minst en andre formulering tilpasset å bli løst opp i en kontrollert hastighet i vomfluider; hvori den ene eller flere mengder av den første formuleringen er tilveiebrakt ved en eller flere forhåndsbestemte lokaliteter i elementet relativt til nevnte ene eller flere mengder av den andre formuleringen for en eller flere forsinkede frigivelser av minst det første aktive middel inn i vommen på forhåndsbestemte tidspunkter før, i løpet, etter eller en hvilken som helst kombinasjon derav, av en forhåndsbestemt forlenget tidsperiode definert ved nevnte andre formulering. Oppfinnelsen angår også en fremgangsmåte for å levere minst et første aktivt middel til vommen hos en drøvtygger på en forsinket måte på et eller flere forhåndsbestemte tidspunkter etter administrasjon til dyret av en sammensetning som inneholder det aktive midlet, fremgangsmåten innbefatter administrasjon til dyret av et kontrollert doseringsfrigivelseselement ifølge oppfinnelsen. Det første aktive midlet vil typisk være for behandling, profylakse eller begge av en sykdom eller befengt tilstand hos en drøvtygger, eller for forandring av den fysiologiske statusen til en drøvtygger.
NO20041941A 2001-10-19 2004-05-10 Doseringsform, utstyr og fremgangsmater for behandling NO20041941L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR8390A AUPR839001A0 (en) 2001-10-19 2001-10-19 Dosage form, device and methods of treatment
PCT/AU2002/001426 WO2003033031A1 (en) 2001-10-19 2002-10-18 Dosage form, device and methods of treatment

Publications (1)

Publication Number Publication Date
NO20041941L true NO20041941L (no) 2004-05-10

Family

ID=3832213

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041941A NO20041941L (no) 2001-10-19 2004-05-10 Doseringsform, utstyr og fremgangsmater for behandling

Country Status (22)

Country Link
US (1) US20050064032A1 (no)
EP (1) EP1448151A4 (no)
JP (1) JP2005510485A (no)
KR (1) KR20050037410A (no)
CN (1) CN1571663A (no)
AR (1) AR037116A1 (no)
AU (5) AUPR839001A0 (no)
BR (1) BR0212975A (no)
CA (1) CA2463674A1 (no)
CR (1) CR7312A (no)
EA (1) EA005778B1 (no)
EC (1) ECSP045063A (no)
HR (1) HRP20040231A2 (no)
HU (1) HUP0401808A3 (no)
IL (1) IL160754A0 (no)
MX (1) MXPA04003679A (no)
NO (1) NO20041941L (no)
NZ (1) NZ531672A (no)
PE (1) PE20030519A1 (no)
PL (1) PL368387A1 (no)
WO (1) WO2003033031A1 (no)
ZA (1) ZA200403743B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRN20030021A1 (it) 2003-07-21 2005-01-22 Ascor Chimici Srl Composizione di materia comprendente particelle contenenti cloruro di colina da somministrare in forma ruminalmente protetta e post-ruminalmente efficace.
ITMI20041820A1 (it) * 2004-09-24 2004-12-24 Ascor Chimici Srl Composizione in micro-pellets a rilascio controllato di sostanze fisiologicamente attive, procedimento di preparazione e relativo impiego nel settore zootecnico.
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
AU2005320547B2 (en) * 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
NZ554260A (en) * 2007-09-30 2010-05-28 Agres Ltd Selenomethionine andor selenocysteine administration to non-human animals to increase selenium content in protein sources
WO2010126857A1 (en) * 2009-04-28 2010-11-04 Wyeth Llc Parasiticidal combinations of macrocyclic lactones and polyether antibiotics
AU2014203209B2 (en) * 2009-07-31 2015-11-26 Boehringer Ingelheim Animal Health USA Inc. Sustained release capsules
EP2459116B1 (en) * 2009-07-31 2019-10-09 Boehringer Ingelheim Animal Health USA Inc. Sustained release capsules
US8980896B2 (en) * 2009-12-17 2015-03-17 Merial, Inc. Compositions comprising macrocyclic lactone compounds and spirodioxepinoindoles
FR2992219B1 (fr) * 2012-06-22 2014-07-11 Aditec Lab Composition pour le traitement de l'hypocalcemie chez les ruminants
MX2017000041A (es) 2014-07-03 2017-05-01 Mallinckrodt Llc Formulaciones de liberacion inmediata disuasivas de abuso que comprenden polisacaridos no celulosicos.
CA3013321A1 (en) 2016-02-08 2017-08-17 SpecGx LLC Glucomannan containing pharmaceutical compositions with extended release and abuse deterrent properties
WO2018102799A1 (en) * 2016-12-02 2018-06-07 Clexio Biosciences Ltd. Gastric residence system
US11147273B2 (en) * 2017-06-26 2021-10-19 Boehringer Ingelheim Animal Health USA Inc. Dual active parasiticidal granule compositions, methods and uses thereof
CA189877S (en) 2017-08-25 2021-02-18 Argenta Mfg Limited Intraruminal device
EP3849525A4 (en) * 2018-09-10 2022-06-08 Argenta Innovation Limited DELAYED RELEASE FORMULATIONS IN DISPENSING DEVICES
BR112021004523A2 (pt) * 2018-09-10 2021-06-08 Argenta Innovation Limited formulações para liberação sustentada em dispositivos de administração
US11478426B2 (en) 2018-09-25 2022-10-25 SpecGx LLC Abuse deterrent immediate release capsule dosage forms
AU2020328595B2 (en) * 2019-08-14 2023-07-13 Elanco Tiergesundheit Ag New wing protector for winged capsule and method of using same
WO2021158946A1 (en) * 2020-02-07 2021-08-12 Elanco Animal Health Incorporated Winged capsule
WO2021242481A1 (en) * 2020-05-28 2021-12-02 Boehringer Ingelheim Animal Health USA Inc. Bi-modal release intra-ruminal capsule device and methods of use thereof
SI4037666T1 (sl) 2020-12-08 2024-09-30 Ruminant Biotech Corp Limited Izboljšave naprav in postopkov za dostavo snovi živalim
CN113398337A (zh) * 2021-06-23 2021-09-17 上海市肺科医院 包含抗结核药物缓释植入人工骨载体的脊柱内固定装置

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU520409B2 (en) * 1977-05-25 1982-01-28 Commonwealth Scientific And Industrial Research Organisation Controlled release composition
GB2077586A (en) * 1980-06-12 1981-12-23 Standard Telephones Cables Ltd Sustained-release device
NZ197543A (en) * 1980-07-02 1984-12-14 Commw Scient Ind Res Org Controlled release compositions for inclusion in intraruminal devices
US4416659A (en) * 1981-11-09 1983-11-22 Eli Lilly And Company Sustained release capsule for ruminants
NZ203203A (en) * 1982-02-16 1985-09-13 Commw Scient Ind Res Org Controlled release device:gas diffusion limited
IE54171B1 (en) * 1982-06-22 1989-07-05 Univ Glasgow Device for introducing nutrients and/or therapeutic materials into ruminant animals
GB8328916D0 (en) * 1983-10-28 1983-11-30 Castex Prod Pharmaceutical pellet
US4777049A (en) * 1983-12-01 1988-10-11 Alza Corporation Constant release system with pulsed release
GR851195B (no) * 1984-06-02 1985-11-25 Castex Prod
US4723958A (en) * 1986-05-23 1988-02-09 Merck & Co., Inc. Pulsatile drug delivery system
US4867980A (en) * 1986-10-10 1989-09-19 Coopers Animal Health Australia Limited Heavy density depot
US5023088A (en) * 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US4874388A (en) * 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
US5110597A (en) * 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US5938654A (en) * 1987-06-25 1999-08-17 Alza Corporation Osmotic device for delayed delivery of agent
US4957494A (en) * 1987-06-25 1990-09-18 Alza Corporation Multi-layer delivery system
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
GB8829089D0 (en) * 1988-12-13 1989-01-25 Coopers Animal Health Intra ruminal device
DE59000232D1 (de) * 1989-02-11 1992-09-10 Bayer Ag Arzneimittel mit kontrollierter wirkstoffabgabe.
US5110598A (en) * 1989-06-30 1992-05-05 Smithkline Beecham Corp. Intermittent release dosage form
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5017381A (en) * 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
MX9200339A (es) * 1991-01-28 1992-08-01 Hoechst Ag Preparado para la liberacion controlada de sustancias activas, que son apropiadas como terapeuticos o para mejorar el crecimiento y el aprovechamiento de los piensos en rumiantes
US5417682A (en) * 1991-01-30 1995-05-23 Alza Corporation Device for administering active agent to biological environment
AU650113B2 (en) * 1991-04-05 1994-06-09 Eli Lilly And Company Sustained release capsule and formulations
US5240713A (en) * 1991-09-27 1993-08-31 Alza Corporation Dual rate agent delivery device
US5221278A (en) * 1992-03-12 1993-06-22 Alza Corporation Osmotically driven delivery device with expandable orifice for pulsatile delivery effect
BR9506533A (pt) * 1994-01-20 1997-09-16 Pastoral Agric Res Inst Nz Ltd Dispositivo para administração de materiais benéficos a ruminantes
AUPM897594A0 (en) * 1994-10-25 1994-11-17 Daratech Pty Ltd Controlled release container
PL205109B1 (pl) * 1998-11-02 2010-03-31 Elan Pharma Int Ltd Wielocząstkowa kompozycja metylofenidatu o modyfikowanym uwalnianiu i jej zastosowanie
US6569857B1 (en) * 1999-05-03 2003-05-27 Drugtech Corporation Dietary supplement
DE19956486A1 (de) * 1999-11-24 2001-06-21 Lohmann Therapie Syst Lts Mehrschichtige Zubereitung zur gesteuerten, pulsartigen Abgabe von Wirkstoffen
EP1251864A4 (en) * 1999-12-31 2006-02-22 Univ Rutgers PHARMACEUTICAL FORMULATION COMPRISING A POLYMERIC MIXTURE AND AN ACTIVE COMPOUND FOR TIME-RELEASED RELEASE
AU2001237424A1 (en) * 2000-02-28 2001-09-12 Akzo Nobel N.V. Bodies for the controlled release of active substances

Also Published As

Publication number Publication date
AR037116A1 (es) 2004-10-20
US20050064032A1 (en) 2005-03-24
EA200400557A1 (ru) 2005-02-24
HUP0401808A3 (en) 2005-11-28
AU2004210542C1 (en) 2009-01-08
CR7312A (es) 2004-10-27
IL160754A0 (en) 2004-08-31
CN1571663A (zh) 2005-01-26
JP2005510485A (ja) 2005-04-21
AU2002332975B2 (en) 2005-02-03
AU2002332975C1 (en) 2009-01-29
PE20030519A1 (es) 2003-06-13
ECSP045063A (es) 2004-05-28
AU2004210542B2 (en) 2005-07-28
ZA200403743B (en) 2005-05-16
AU2009250987A1 (en) 2010-01-14
CA2463674A1 (en) 2003-04-24
AU2004210542B9 (en) 2005-09-01
PL368387A1 (en) 2005-03-21
EP1448151A4 (en) 2010-01-13
AU2005227413A1 (en) 2005-11-17
WO2003033031A1 (en) 2003-04-24
EP1448151A1 (en) 2004-08-25
HRP20040231A2 (en) 2004-08-31
AU2004210542A1 (en) 2004-09-30
KR20050037410A (ko) 2005-04-21
MXPA04003679A (es) 2004-07-23
HUP0401808A2 (hu) 2005-01-28
EA005778B1 (ru) 2005-06-30
NZ531672A (en) 2006-08-31
AU2002332975B9 (en) 2005-03-17
BR0212975A (pt) 2004-10-13
AUPR839001A0 (en) 2001-11-15

Similar Documents

Publication Publication Date Title
NO20041941L (no) Doseringsform, utstyr og fremgangsmater for behandling
Yaniz et al. Recent developments in oestrous synchronization of postpartum dairy cows with and without ovarian disorders
Roehrborn et al. Safety and efficacy of alfuzosin 10 mg once‐daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double‐blind, placebo‐controlled studies
Yemisci et al. Effects and side‐effects of spironolactone therapy in women with acne
AR048439A1 (es) Composiciones farmaceuticas y metodos para tratar la infeccion por vih
AR038157A1 (es) Formas de dosificacion de benzimidazoles sustituidos y su uso
AR076153A1 (es) Forma de dosificacion intra-oral de multiples porciones con propiedades organolepticas. formulaciones
MX2008013828A (es) Combinacion farmaceutica que comprende 3-(3-dimetilanimo-1-etil-2- metil-propil)-fenol y un nsaid.
KR20090057349A (ko) 레보도파／칼비도파의 ２４시간의 장기간 장내투여
EP1186303A3 (en) Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
EP1202725A4 (en) METHOD FOR TREATING THE SYMPTOMS OF HORMONAL CHANGES, INCLUDING HOT WASHES
Saracho et al. Evaluation of the losartan in hemodialysis (ELHE) study
Gisbert et al. Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment?
Malfertheiner et al. What constitutes failure for Helicobacter pylori eradication therapy?
Murakami et al. Tu1056 a phase 3, double-blind study of a triple therapy with TAK-438, amoxicillin, and clarithromycin as first line eradication of H. pylori and a triple therapy with TAK-438, amoxicillin, and metronidazole as second Line eradication of H. pylori
Gravis Ultrastructural observations on spermatozoa retained within the seminiferous epithelium after treatment with dibutyryl cyclic AMP
MY122477A (en) Sertraline oral concentrate
Singh et al. Nonsurgical management of chyluria (sclerotherapy)
Caixeta et al. Contrast‐induced nephropathy: Protective role of fenoldopam
AR037543A1 (es) Metodo para la terapia del cancer y composicion farmaceutica
Motta et al. A novel and safe strategy for resynchronization using estradiol 14 days after timed-ai in beef heifers
Kovacs et al. Double‐blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2‐receptor antagonists
Basyigit et al. The impact of bismuth addition to sequential treatment on Helicobacter pylori eradication: A pilot study
Jones Etodolac (Lodine®): Profile of an established selective COX-2 inhibitor
RU2732407C1 (ru) Фармацевтическая композиция, содержащая палоносетрон в качестве активного ингредиента

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application